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Abstract 
Aims/hypothesis In adults, the rate of beta-cell replication is normally very low but recent 
evidence implies that it may increase during insulitis. We have studied patients with recent-
onset type 1 diabetes to establish whether islet cell proliferation is increased during the 
disease process.  
Methods Paraffin-embedded pancreatic sections from 10 patients with recent onset type 1 
diabetes, and a range of relevant controls, were stained by immunohistochemical techniques 
with antibodies against the proliferation markers, Ki67 and minichromosome maintenance 
protein-2 (Mcm-2). A combination staining technique involving both immunoperoxidase and 
immunofluorescence methods was developed to quantify the numbers of alpha- and beta-cells 
having Ki67-positive nuclei and to investigate the relationship between insulitis and islet cell 
proliferation. 
Results In non-diabetic control subjects, only 1.1±0.3% of islets contained one or more Ki67+ 
islet cells, whereas this proportion was increased markedly in recent-onset type 1 diabetes 
(10.88±2.5%; p<0.005). An equivalent increase in Ki67+ staining occurred in both alpha and 
beta cells and was correlated positively with the presence of insulitis. A significant increase 
in the labelling of islet cells in type 1 diabetes was also seen when Mcm-2 staining was 
employed. Increased islet cell proliferation was not evident in 3 patients with longer duration 
type 1 diabetes or in 10 type 2 diabetic patients.  
Conclusions/Interpretation This study reveals that both alpha and beta cells undergo a 
marked increase in proliferation during the progression of type 1 diabetes in humans. The 
results imply that islet cell proliferation is re-initiated in response to the autoimmune attack 
associated with type 1 diabetes.  
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Introduction 
Type 1 diabetes is a T cell-mediated autoimmune disease in which the insulin-secreting beta 
cells of the islets of Langerhans are destroyed selectively [1].  Clinical symptoms arise when 
~70% of the total beta cell mass is lost and this process follows a relatively protracted time 
course (months to years) during which the net rate of cell loss must exceed the rate of beta-
cell replacement [2].  
Beta-cell proliferation has been studied to only a limited extent in humans but the available 
evidence implies that this process occurs at relatively high levels during the first two years of 
life and declines rapidly thereafter [3, 4]. However, it is also clear that, at least in animals, 
beta cell proliferation can be re-induced in adulthood under conditions when insulin 
resistance is increased, for example during pregnancy or in obesity [5-7]. This suggests that 
beta cells may retain an intrinsic capacity to replicate but that they become largely quiescent 
during early childhood. 
Recent evidence from a single case report [8] has revealed that enhanced proliferation of 
beta-cells occurred in an adult human subject who was characterised as “pre-diabetic” by 
virtue of the presence of circulating islet autoantibody positivity and active insulitis on 
histological examination of the pancreas. This proliferative response was observed prior to 
the onset of clinical symptoms, thereby raising the possibility that a compensatory increase in 
beta cell proliferation may occur early in the development of type 1 diabetes in humans. This 
would be consistent with evidence from animal models where enhanced beta-cell 
proliferation has also been seen early in the disease process [9-11], but this evidence differs 
from the conclusions of Butler et al. [12] who did not detect enhanced beta cell replication in 
pancreas sections recovered from a cohort of newly-diagnosed type 1 diabetes patients. It is 
important, therefore, to clarify whether enhanced beta cell proliferation occurs during the 
course of human type 1 diabetes. If this were to be the case, then a window of opportunity for 
therapeutic intervention might be considered as a means to replenish the beta cell mass, in 
parallel with attempts to limit the rate of autoimmune-mediated cell loss. One recent study 
has reported the detection of insulin-positive cells in 88% (37/42) of patients with long 
standing type 1 diabetes, therefore the window of opportunity in which intervention with 
potential regenerative therapies may be substantial [13]. 
In order to address this issue more fully, we have analysed pancreatic tissue from a cohort of 
patients with recent onset type 1 diabetes. Two independent markers of cell proliferation have 
been studied using both light and fluorescence microscopy to identify and quantify 
proliferating endocrine cells. 
Methods. 
Subjects 10 human pancreases recovered from patients with recent onset type 1 diabetes 
(disease duration ≤ 18 months) were selected from within a cohort used previously [14]. 
The selection was achieved randomly except that any specimens which had been post-fixed 
in mercuric chloride were excluded, as this fixative proved unsuitable for labelling with 
certain antibodies. The specimens used had been fixed in buffered p-formaldehyde, un-
buffered formol saline or Bouin’s fixative and they were all paraffin-embedded. 9 of the 10 
pancreases were removed at autopsy (D1-D9) and one was recovered at the time of organ 
donation (D10). Nine of the patients were in the age range 1-23 years (mean 10.9±2.4). One 
female patient was 42, raising the overall mean to 14±3.8 years (Table 1). Pancreatic 
specimens from 14 non-diabetic (10 paediatric (C1-C10), 4 adult(C11-C14; surgical 
specimens, healthy regions utilised)), 10 type 2 diabetic patients (C15-C24), 3 patients with 
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long duration type 1 diabetes (C25-C27), 12 patients with pancreatitis (9 chronic (C28-C36), 
2 autoimmune (C37-38) and 1 obstructive (C39)) and 9 non-diabetic patients which were age 
matched with the type 2 diabetic patients (C40-C48) were also studied. Full details are listed 
in Electronic Supplementary Material [ESM] Table 1. Sections of human tonsil and 
pancreatic lymph node were used as positive control tissues for markers of cell proliferation. 
The current investigation was performed with full ethical approval from the Research Ethics 
Committee, Glasgow Royal Infirmary, UK. 
 
Immunohistochemistry Serial sections (4µm) were mounted on glass slides coated in (3-
Aminopropyl)-triethoxysilane (Sigma Aldrich, Dorset, UK). Sections were processed and 
labelled using a standard immunoperoxidase technique for paraffin sections. Heat-induced 
epitope retrieval (HIER) was performed by heating the sections in a pressure cooker in a 
microwave oven on full power (800W) for 20 min followed by 20 min of cooling at room 
temperature. 1 mM EDTA (Sigma Aldrich) buffer pH 8.0 was used to unmask Ki67 and 10 
mM citrate (Sigma Aldrich) buffer pH 6.0 was used for minichromosome maintenance 
protein 2 (Mcm-2). Details of all primary antibodies are listed in Table 2. Sections were 
incubated in primary antibody for 1 h at room temperature. Dako REAL™ Envision™ 
Detection System was used for antigen detection. Sections were counterstained with 
hematoxylin (Dako). Some slides were processed in the absence of primary antibody or with 
isotype control antisera to confirm the specificity of labelling. 
 
Combined immunoperoxidase and immunofluorescence immunohistochemistry A 
combination technique was used in which sections were dual stained using both the 
immunoperoxidase technique described above, followed by immunofluorescence labelling of 
the same sections. Anti-Ki67 and anti-Mcm-2 were detected on separate sections using the 
immunoperoxidase technique while the endocrine cells and lymphocytes were detected using 
immunofluorescence. After counterstaining with hematoxylin, Ki67 immunoperoxidase-
stained sections from patients with recent on set type 1 diabetes and the non-diabetic controls 
were incubated with primary antibodies against eith r insulin and glucagon or insulin and 
somatostatin or insulin and CD45 or glucagon and CD45. Mcm-2 stained sections were 
further incubated with antibodies against either insulin or CD45. Sections from chronic 
pancreatitis patients were further incubated in a cocktail of antibodies against insulin and 
glucagon. The antibodies were detected with goat AlexaFluor® 488 or 568 conjugated 
secondary antibodies (Invitrogen, Paisley, UK). DAPI (1:1000, Invitrogen) was included in 
the final secondary incubation to stain cell nuclei. Nine of the 10 type 1 diabetic patients were 
found to be suitable for analysis by this method, while the tissue from one patient failed to 
absorb the DAPI nuclear stain. Sections were mounted in Vectashield hard-set mounting 
medium (Vector Laboratories, Peterborough, UK) under glass cover slips.  
The sections were analysed initially using the brightfield function of a Nikon Eclipse 80i 
microscope (Nikon, Surrey, UK) and a monochrome photomicrograph was captured for each 
islet that contained at least one Ki67+ cell. The fluorescence imaging function of the 
microscope was then used to capture immunofluorescence staining. The images were 
precisely overlaid using NIS-Elements BR 3.0 software (Nikon) to determine the endocrine 
cell sub-type of the Ki67+ or Mcm-2+ cells. 
Staining analysis Islets were identified morphologically in each pancreas section after 
counter-staining with hematoxylin. Initially all islets on each section from every patient were 
assessed for the presence of Ki67+ or Mcm-2+ nuclei and the percentage of islets containing 
one or more immunopositive cells per section was recorded. Using the combination imaging 
technique described above, the identity of each of the cells having Ki67+ nuclei was 
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determined. In islets which were infiltrated with immune cells (which could be readily 
identified by their unique morphology) any Ki67+ cell that was evidently an immune cell was 
excluded from the analysis. A Ki67 labelling index was determined for both the alpha and 
beta cells in the non-diabetic control and type 1 diabetic patient groups according to the 
percentage of each islet cell type that was positively stained for Ki67. Cell counting was 
carried out using Adobe® Photoshop® CS4 software. Islets were categorised as insulitis-
positive if there were ≥5 CD45+ cells within the islet perimeter [14]. 
 
Statistical analysis The percentage of Ki67+ or Mcm-2+ islets per section is expressed as the 
mean ± SEM and statistical significance was calculated by Students t-test using SPSS 16 
software. The statistical significance of differences in the labelling index of islet cells and 
also the insulitis correlation was calculated using χ2 analysis. 
 
Results  
The percentage of islets with Ki67 positive islet cells is increased in recent onset type 1 
diabetic patients compared to non diabetic controls. For the initial analysis, one pancreas 
section from each of 10 recent onset type 1 diabetic patients and 14 age-matched non-diabetic 
controls was stained with an anti-Ki67 antibody and the percentage of islet sections having at 
least 1 Ki67+ nucleus was calculated. A mean of only 1.1±0.3% Ki67+ islets per pancreas 
section (range: 0-1.5%) was recorded in the non-diabetic controls. This number was increased 
by more than 10 fold in the recent onset type 1 diabetic group to 10.9±2.5% (p<0.005) of 
islets per section (range: 1.5-31.8%) (Fig. 1a; Table 3). A typical Ki67+ islet from a type 1 
diabetic patient is shown in Fig. 1b.  
Overall, a total of 1280 islet sections were examined in the type 1 diabetic group and 4031 
islet sections in the controls. Within the type 1 diabetic group, a mean of 37.1±8.2% (range: 
6.7-78.4%) of the total islet sections were insulin-positive.  Of the population of islet sections 
that were Ki67+, 23% were insulin-negative, suggesting that the increase in proliferation was 
not restricted solely to beta cells. The mean area per islet was calculated for the recent-onset 
type 1 patients and the non-diabetic controls. These values were 18227±1054 µm2 for insulin 
positive and 9017±1139 µm2 for insulin-negative islets in the type 1 diabetic group and 
12265±1095 µm2 in the non-diabetic controls. 
The increase in Ki67+ islet cells seen in recent on-set type 1 diabetes occurs in both alpha 
and beta cells. To determine which islet cells expressed Ki67 in recent-onset type 1 diabetes, 
sections from 9 patients were analysed in greater detail. Each section was co-stained with 
anti-Ki67 (immunoperoxidase) and combinations of anti-insulin, anti-glucagon and anti-
somatostatin (immunofluorescence). The sections were photomicrographed under brightfield 
illumination to capture images of the islets containing at least one Ki67+ islet cell. 
Fluorescence images of the staining patterns of insulin, glucagon and somatostatin were 
captured subsequently and the images were overlaid (Fig. 2a-g; [ESM 2 and 3]).  
The Ki67 labelling index was 0.006% for alpha cells and 0.008% for beta cells in the sections 
from control subjects. The labelling index of both cell types increased significantly in the 
recent onset type 1 diabetic group to 0.066% (alpha) and 0.07% (beta cells) respectively (χ2 
p<0.001)  (Fig. 3). The number of Ki67+ delta cells was insufficient to allow accurate 
quantification of a labelling index. 
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The topography of the staining patterns precluded unequivocal identification of 10-20% of 
the Ki67+ islet cells in both the recent onset type 1 diabetic pancreatic sections and the non-
diabetic controls. 
Increased proliferation of  islet cells in type 1 diabetes is also seen using a second marker of 
cell proliferation. Ki67 is a widely used marker of cell proliferation however, it was 
considered important to confirm the presence of proliferating cells with a second 
proliferation-specific protein, unrelated to Ki67. Mcm-2 was chosen for this purpose and 
pancreas sections from the 10 type 1 diabetic and 14 non-diabetic control patients were 
stained with an anti-Mcm-2 antibody using the immunoperoxidase technique. A mean of 
2.4±0.5% (range: 0-7.1%) islets per section had at least one Mcm-2+ cell in the control 
group. This was a statistically higher percentage than that found with the Ki67 antibody in the 
equivalent subjects (p<0.05) which may reflect the longer period of expression of Mcm-2 vs 
Ki67 during the cell cycle, as revealed by the staining patterns seen with these markers in 
tonsil epithelium [ESM 4]. In this tissue, the oral mucosa cells divide at the base of the 
stratified squamous epithelium and migrate towards the surface after division. Mcm-2+ cells 
were detected further from the dividing layer than those stained with Ki67, consistent with 
the longer persistence of Mcm-2 after mitosis. Staining of sections from the type 1 diabetic 
group confirmed a marked increase in the rate of proliferation of  islet cells (to 11±2.6% of 
islets; p<0.001 vs control; Fig. 4a). A representative islet section stained positively for Mcm-
2 is shown in Fig. 4b. 
Pancreas sections from 3 of the 10 recent onset type 1 diabetic patients were double-stained 
with anti-Mcm-2 and anti-insulin in order to assess the percentage of Mcm-2+ beta cells. 54 
Mcm-2+ islets were examined and, among these, a total of 142 Mcm-2+ cells were detected. 
Of the Mcm-2+ cells, 60 (42%) were dual-positive for insulin, thereby confirming that these 
were beta cells (Fig. 4c and d). 
To confirm that the majority of Mcm-2+ cells were islet cells rather than infiltrating 
lymphocytes, dual staining was performed with anti-Mcm-2 and anti-CD45. 21 Mcm-2+ 
islets that were heavily infiltrated with CD45+ lymphocytes were examined in detail. Very 
few of the infiltrating CD45+ cells were co-positive for Mcm-2 (Fig. 4e). Peripancreatic 
lymph nodes were often present adjacent to the pancreas sections and dual staining revealed 
the presence of Mcm-2+ CD45+ cells, demonstrating that immunoperoxidase staining of the 
nucleus with anti-Mcm-2 had not interfered with the ability of the CD45 antibody to stain the 
lymphocyte cell surface (Fig. 4f). 
The presence of Ki67+ islet cells correlates with insulitis in type 1 diabetes. Pancreas 
sections were stained to assess the relationship between insulitis and Ki67-positivity in islet 
cells. Insulitis was defined as the presence of 5 or more CD45+ lymphocytes within the islet 
perimeter [14]. A total of 1091 islet sections were examined from 8 patients and 247 of these 
(22.6%) were insulitis-positive. Among this group, 44/247 islets (17.8%) contained one or 
more Ki67+ islet cell.  Of these 44 islets, 42 were also insulin-containing islets. By contrast, 
only 22 of the 844 insulitis negative islets (2.6%) contained a Ki67+ islet cell. Of these 22 
islets, 7 were insulin-containing (Fig. 5a and b). Thus, there was a 7-fold increase in the 
frequency with which Ki67+ islet cells were detected in islets containing infiltrating immune 
cells compared to those that were insulitis-negative (χ2 p<0.001). In order to verify this 
conclusion, we also compared the proportion of insulin-containing islets that were both 
Ki67+ and inflamed (42 of 405 (10.4%)) with those that were Ki67+ but not inflamed (7 of 
405 (1.7%)). This large difference is consistent with the proposition that proliferation 
correlates with the inflammatory response. Additional support was obtained by a direct 
Page 6 of 26
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
comparison of the Ki67 labelling index for Ki67+/Insulin+ cells in inflamed vs non-inflamed 
islets, which yielded significantly different values of 0.097% and 0.004% (P<0.0005), 
respectively (Fig. 5c).  
Increased Ki67+ labelling of islet cells is not maintained in patients having longer duration 
type 1 diabetes. To establish whether the increase in proliferating islet cells is persistent, 
pancreatic sections from 3 type 1 diabetic patients with a longer disease duration (6, 12 and 
12 years respectively) were stained with the anti-Ki67 antibody. One of these patients 
(disease duration of 12 years) still retained some residual beta cells within 53/79 of their islet 
sections while the other patients were entirely beta cell deficient in the available sections. No 
Ki67+ islet cells were detected in any of the 561 islet sections examined in these patients 
(Table 3). 
Increased Ki67+ labelling of islet cells is not observed in patients with type 2 diabetes. To 
determine whether the increase in islet cell proliferation was restricted to patients with 
(recent-onset) type 1 diabetes, pancreatic sections from 10 patients with type 2 diabetes were 
also stained with the Ki67 antibody. A total of 1436 islets were examined and the mean 
percentage of Ki67+ islets per section (1.5±0.16%; 3 patients had no Ki67+ cells) was 
statistically lower than that of the recent onset type 1 diabetic group (P<0.005) but not 
different from the non-diabetic control patients (P=0.55; Table 3). The type 2 diabetic 
patients were also compared with 9 age matched non-diabetic control patients stained for 
Ki67. In this group a mean of 0.97±0.37% of islets per section contained Ki67+ cells which 
was not statistically different from the type 2 diabetic patients (P=0.5; Table 3). 
Increased Ki67+ labelling of  islet cells is not observed in patients with pancreatitis. Since 
the increased proliferation detected in patients with recent-onset type 1 diabetes correlated 
with immune cell infiltration, it was also considered important to examine the pancreas of 
patients with a different inflammatory disease of the pancreas, pancreatitis. Accordingly, 
pancreatic sections from 12 patients with either chronic, autoimmune or obstructive 
pancreatitis were stained using the combination technique for Ki67, insulin and glucagon. Of 
the 12 samples analysed (2989 islets in total), three did not contain any Ki67+ cells within 
islets. In the remaining nine sections 82 out of 2651 islets examined contained a total of 139 
Ki67+ cells. Of these, 42 were identified as endocrine cells (14 alpha and 26 beta) and 99 
were non-endocrine cells (Fig. 6a-c). In these samples no attempt was made to study small 
clusters of endocrine cells associated with pancreatic ducts.  
Discussion 
The rate of islet endocrine cell proliferation in humans varies with age. A wave of 
proliferation occurs early in postnatal life as the endocrine pancreas is released from the 
intrauterine environment and is remodelled to meet the demands of independent living and 
changing nutrition [3]. This period is, however, short-lived, and is followed by a rapid decline 
in the proliferation rate which then stabilises at an extremely low level that is maintained 
throughout childhood and into adult life. A similar situation may also pertain in other 
mammalian species although, in some species, islet cell proliferation can be re-induced 
during adulthood by the imposition of increased metabolic demand (e.g. during obesity) and 
also in response to the hormonal adaptations associated with pregnancy [6, 7].  Importantly, 
we now demonstrate that islet cell proliferation is increased in humans during the ongoing 
process of insulitis and autoimmunity associated with the recent onset of type 1 diabetes.  
We have employed immunohistochemical detection of two independent proteins expressed 
uniquely during cell division, to study the proliferation of islet cells. Ki67 is widely used as a 
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marker of cell division in fixed tissue as it is expressed specifically during all stages of the 
cell cycle but is degraded before cells re-enter G0 [15]. Mcm-2 plays a role in DNA 
replication and is expressed from early G1 through the remaining phases of the cell cycle but, 
is degraded prior to entry into G0 [16]. We analysed both proteins and found that they were 
detected at higher frequency in the nuclei of islet cells from patients with recent onset type 1 
diabetes than in non-diabetic controls. Detailed analysis revealed a 10-fold increase in the 
proportion of islets displaying one or more Ki67+ cells in the patient samples vs controls. 
The increase was somewhat lower when the labelling of Mcm-2 was assessed (approximately 
5-fold) but remained statistically significant. The reduction in the magnitude of the response 
seen when assessing Mcm-2 was principally due to the larger proportion of islet sections 
from control subjects which displayed Mcm-2 immunopositivity compared to those which 
were positive for Ki67. The reasons for this difference may reflect the varying periods of the 
cell cycle when each protein is expressed. Analysis of the islet cells which display increased 
proliferation in the islets of patients with recent onset type 1 diabetes revealed that the 
labelling index of both alpha and beta cells for Ki67+ was enhanced by approximately 10-
fold. Thus, unlike the process of immune-mediated islet cell destruction (which is entirely 
beta cell specific) the proliferative response appears not to display such cell specificity.   
The increase in islet cell proliferation correlated closely with the presence of insulitis 
suggesting that a signal(s) emanating from infiltrating immune cells might mediate the 
enhanced proliferative response. Consistent with this hypothesis, an increase in islet cell 
proliferation has also been reported in the inflamed islets of a patient classified as having 
‘pre-diabetes’ [8]. In addition, an 89 year old man recently diagnosed with type 1 diabetes, 
had increased Ki67+ islet cells and it was noted that this patient also had insulitis in a large 
percentage of islets [17]. Taken together, these results support the suggestion that human islet 
cell proliferation can be increased during islet inflammation. Moreover, our finding that 
patients with a long duration of diabetes do not display islet cell proliferation also support 
this conclusion since islet inflammation was minimal in these patients. 
Additional support for the possible involvement of immune-derived signals as mediators of 
islet cell proliferation comes from the NOD mouse and the biobreeding (BB) rat. In the NOD 
model, beta cell proliferation is increased during the pre-diabetic phase and this has been 
attributed to the presence of insulitis in the relevant islets [9, 10]. The BB rat also has a 
higher than normal islet cell Ki67 labelling index during the pre-diabetic period when the 
islets are infiltrated by mononuclear cells [18]. Similar findings have also been reported in a 
partial pancreatectomy model in the LEW.Han rat [19] although, unlike our present findings 
in man, the alpha cell proliferation was unchanged in these animals.  
Examination of pancreatic sections from patients with pancreatitis, another inflammatory 
disease of the pancreas, revealed low numbers of Ki67+ alpha or beta cells which was not 
consistent with a large-scale proliferative response. However, a significant increase in beta 
cell replication has been reported previously in sections from patients with severe pancreatitis 
suggesting that, under these circumstances, the immune cells may elaborate a stimulus for 
endocrine cell proliferation [20]. One study has also reported neogenesis of duct epithelial 
cells in to insulin-producing cells in patients with chronic pancreatitis [21].  
We have not characterised the nature of the putative immune cell derived-signal which may 
promote islet cell proliferation but very low concentrations of certain pro-inflammatory 
cytokines (including IL-1β) can elicit beta cell proliferation in isolated human islet 
preparations [22]. Higher doses of these same cytokines are cytotoxic suggesting that the 
gradient of concentration to which islet cells are exposed may determine their ultimate fate. 
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Conceivably, therefore, the initial influx of immune cells might promote endocrine cell 
proliferation and this response is ultimately over-ridden by a net cytotoxicity as the 
concentration of immune mediators increases further. It is important to note, however, that 
we did not detect an increase in Ki67+ islet cells in pancreas sections from patients with type 
2 diabetes. This form of diabetes has recently been shown to be associated with a low-level 
macrophage infiltration of the islets but there is no lymphocyte infiltration [14, 23, 24]. 
Hence, this implies that a signal other than IL-1β (which is secreted by macrophages but not 
by T- or B-lymphocytes) may be primarily responsible for mediating the proliferative 
response. The finding that islet cell proliferation is not increased in patients with type 2 
diabetes also implies that hyperglycaemia is unlikely to represent a primary stimulus for the 
proliferative response since this is a feature of both forms of the disease.  
The present results differ from the recent findings of Butler et al. who did not find any 
increase in beta cell proliferation in a cohort of patients with recent onset type 1 diabetes 
[12]. If, as we propose, the proliferative response reflects an early response to insulitis, then 
this may have been undetectable in several of the samples examined by Butler et al. [12] 
since four of the nine patients studied did not display insulitis. However, other undefined 
factors might also account for the differences.  
In summary, the current study reveals that islet cell proliferation is increased in the islets of 
patients with recent onset type 1 diabetes. This correlates with inflammation and suggests that 
the immune cells elaborate a signal which promotes islet cell mitosis. These results suggest 
that, if mechanisms could be found to facilitate cell proliferation during the pre-diabetic 
phase, then it may be possible to facilitate the regeneration of beta cells as a therapeutic 
intervention in patients progressing to type 1 diabetes.  
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Table 1 Details of patients with recent onset type 1 diabetes 
Patient 
 
Age Gender Duration of 
diabetes 
 Cause of death No. 
Islets 
No. 
Ki67+ 
Islets 
No. 
ICIs 
No. ICI  
with 
Insulitis 
No. IDI with 
Insulitis 
D1 1 F 3 days  Ketoacidosis 149 11 10 10 21 
D2 4 F 3 weeks  Ketoacidosis 132 16 32 22 5 
D3 6 F <1 week  Ketoacidosis 37 4 29 10 0 
D4 7 F Unspecified 
but recent 
 Ketoacidosis 90 8 42 3 2 
D5 11 F 5 days Ketoacidosis 132 14 30 26 15 
D6 13 M 2 days Ketoacidosis 86 7 21 14 2 
D7 15 M 6 months Ketoacidosis 204 3 21 9 8 
D8 18 M 4 months Hypoglycaemia 73 23 57 17 0 
D9 23 M 2 weeks Ketoacidosis 103 12 65 6 0 
D10 42 F 18 months Glioma raised 
intracranial 
pressure 
274 17 45 24 7 
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Table 2. Details of primary antibodies used. 
Antigen Cell type Species Dilution Source 
Ki67 Proliferating Mouse 1/200 Dako, Ely, Cambridgeshire, UK 
Mcm-2 Proliferating Rabbit 1/2000 Abcam, Cambridge, UK 
Insulin Beta Guinea pig 1/600 Dako 
Glucagon Alpha Rabbit 1/300 Dako 
Somatostatin Delta Rabbit 1/200 Abcam 
CD45 Lymphocytes Mouse 1/750 Dako 
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Table 3 The mean percentage of Ki67+ islets detected in the patient groups. 
Patient group 
 
No. patients No. islets examined Mean(±SEM) % Ki67+ 
islets 
Non-diabetic controls  14 4031 1.1±0.3 
Recent onset type 1 diabetics 10 1280 10.9±2.5a,b 
Long duration type 1 diabetics 3 561 0 
Type 2 diabetics 10 1436 1.5±1.6c 
Non-diabetic controls age 
matched with type 2 diabetics 
9 3078 0.97±0.37d 
asignificantly greater than non-diabetic controls (p<0.005); 
bsignificantly greater than patients with type 2 diabetes (p<0.005); 
cnot significantly different from non-diabetic controls (p=0.55).  
dnot significantly different from type 2 diabetic patients (p=0.5) 
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Figure Legends 
Fig. 1 Ki67+ islet cell staining. (a) The histogram shows the mean percentage of islets per 
section with ≥1 Ki67+ cells in the recent on set type 1 diabetic and non-diabetic control 
patients (** P < 0.005). (b) A photomicrograph of Ki67+ cells (brown) in an islet of a type 1 
diabetic patient, counterstaining with hematoxylin is seen in purple. Scale bar = 20 µm. 
Fig. 2 Photomicrographs of islets from type 1 diabetic patients stained using the combination 
technique to determine the cell type of the Ki67+ nuclei. (a) An islet showing insulin (green), 
glucagon (red) and Ki67 (dense black nuclei). The white and orange boxes highlight the areas 
which are focused on in images (b) and (c) respectively which demonstrate Ki67+, insulin+ 
cells indicative of proliferating beta cells. (d) An islet showing insulin (green), glucagon (red) 
and Ki67 (dense black nuclei). The white box highlights the area focused on in image (e) 
which indicates a Ki67+ alpha cell. In images a-e cell nuclei are stained with DAPI (blue). (f) 
A brightfield image of the islet demonstrated in (a). Ki67+ nuclei are visible in brown and 
counterstaining with hematoxylin in purple. The black boxes highlight the two areas which 
are focused upon in images (b) and (c). (g) A brightfield image of the islet demonstrated in 
(d). The black box highlights the nucleus that is focused upon in image (e). Scale bars = 20 
µm. 
Fig. 3 Ki67 labelling index for alpha and beta cells. The red bars show the percentage of total 
Ki67+ alpha cells detected in both the non-diabetic control group and the recent onset type 1 
diabetic group (***P<0.001) and the green bars indicate the percentage of Ki67+ beta cells 
detected in both patient groups (***P<0.001). 
Fig. 4 Mcm-2+ islet cell staining. (a) The  histogram shows the mean percentage of islets per 
section with ≥1 Mcm-2+ cells in type 1 diabetic and non-diabetic control patients (* P < 
0.05). (b) Photomicrograph demonstrating the presence of Mcm-2+ cells within an islet of a 
type 1 diabetic patient. (c) Combination staining of Mcm-2 (dense black nuclei) and insulin 
(green) indicated the presence of proliferating beta cells in a type 1 diabetic patient. The 
white box highlights the area which is focused upon in (d) showing a Mcm2+ insulin+ cell. 
(e) The combination technique was used to stain the type 1 diabetic patients for Mcm-2 
(dense black nuclei indicated by red arrows) and CD45 (green) to demonstrate that the 
increased number of Mcm-2+ nuclei in the type 1 diabetic patients vs. controls is not due to 
lymphocyte staining. (f) Staining of a pancreatic lymph node (on the same section as image e) 
demonstrates that the Mcm-2 immunoperoxidase staining does not disrupt the cells ability to 
also stain positively for CD45. Scale bars = 20 µm.  
Fig. 5 Ki67+ islets show a correlation with insulitis in type 1 diabetic patients. (a) The flow 
diagram shows the distribution of Ki67+ islets in 8 type 1 diabetic pancreas sections. The 
total number of islets (1091) was divided into those which were insulitis+ or insulitis-. The 
number of Ki67+ islets in each category was counted and 66 Ki67+ islets were present in 
total. The Ki67+ islets were subdivided into those which were insulin+ or insulin- according 
to the presence or absence of positive insulin immunostaining. (b) The photomicrograph 
demonstrates the presence of insulitis in an islet stained for insulin (green), CD45 (red), 
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DAPI for nuclei in blue and Ki67 (dense black nuclei highlighted by the white arrow) using 
the combination technique, scale bar = 20 µm. (c) The histogram represents the percentage of 
Ki67+ insulin+ cells in insulitis-negative and insulitis-positive islets in recent onset type 1 
diabetic patients. The insulitis-negative group comprised a total of 844 islets and the insulitis-
positive group contained 247 islets, (***P<0.0005). 
Fig. 6 A Ki67+ islet in a patient with chronic pancreatitis. (a) The photomicrograph shows 
insulin (green), glucagon (red) and Ki67 (dense black nuclei) and DAPI (blue). (b) The image 
shows the region from image A which is highlighted by the white box at the bottom left. The 
green insulin staining is indicative of the black nucleus having a beta cell phenotype. (c) The 
image  shows the region from image (a) which is highlighted by the top right white box. The 
red glucagon staining surrounding the black nuclei indicates that this nucleus has an alpha 
cell phenotype. Scale bar = 20 µm. 
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Figure 1. 
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d e
B 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5.  
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Figure 6. 
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Electronic supplementary material Table 1 Details of control patients 
Patient 
 
Age Gender Illness Cause of death (if 
applicable) 
No. Islets No. Ki67+ 
islets 
C1 2 F  Bronchopneumonia 
and epilepsy 
403 6 
C2 2 M  Haemophilus 
influenzae meningitis 
303 5 
C3 3 F  Road traffic accident 337 4 
C4 3 M  Meningococcal 
septicaemia 
276 1 
C5 3 F   277 2 
C6 4 F   390 0 
C7 5 M  Mental handicap 325 1 
C8 6 M  Meningitis following 
head injury 
270 9 
C9 6 M  Porencephaly and 
pneumonia 
295 8 
C10 11 M   302 2 
C11 38 M Carcinoma of 
ampulla of Vater                            
 98 2 
C12 40 M Insulinoma  181 1 
C13 50 F Insulinoma  345 0 
C14 53 F Insulinoma  229 1 
C15 70 F Type 2 diabetes  122 0 
C16 72 F Type 2 diab tes  164 1 
C17 75 F Type 2 diabetes  74 0 
C18 75 F Type 2 diabetes  170 2 
C19 46 F Type 2 diabetes Hypoglycaemia 133 0 
C20 56 M Type 2 diabetes  70 2 
C21 64 F Type 2 diabetes Following 
cholecystectomy 
161 3 
C22 71 M Type 2 diabetes Leg gangrene 169 1 
C23 71 F Type 2 diabetes Myocardial infarction 224 2 
C24 73 M Type 2 diabetes Meningitis 149 10 
C25 20 M Type 1 diabetes  
(duration 6years) 
 106 0 
C26 22 M Type 1 diabetes 
(duration 12years) 
 376 0 
C27 25 F Type 1 diabetes 
(duration 12years) 
Pulmonary 
hypertension 
79 0 
C28 40 M Chronic pancreatitis  247 5 
C29 65 M Chronic pancreatitis  144 0 
C30 Unknown M Chronic pancreatitis  67 0 
C31 Unknown M Chronic pancreatitis  762 7 
C32 33 F Chronic pancreatitis  100 16 
C33 35 M Chronic pancreatitis  577 21 
C34 49 M Chronic pancreatitis  127 0 
C35 53 F Chronic pancreatitis  389 10 
C36 55 M Chronic pancreatitis  137 4 
C37 27 M Autoimmune 
pancreatitis 
 151 9 
C38 55 F Autoimmune 
pancreatitis 
 180 7 
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C39 65 M Chronic obstructive 
pancreatitis 
 108 3 
C40 52 F  Perforated bowel 
cancer 
42 0 
C41 63 F  Subarachnoid 565 0.7 
C42 63 M  Lung cancer 302 2.9 
C43 68 M  Ruptured oesophagus 439 2.9 
C44 68 M  Lung cancer 438 0.7 
C45 69 F  Gall bladder cancer 311 0.3 
C46 71 M  Lung cancer 435 0.2 
C47 76 M  Stroke 300 0.6 
C48 78 F  Ascending cholangitis 246 0.4 
Note: In patients with pancreatitis (C28-C39) the majority (~ 70%) of Ki67+ cells detected in islets did not stain 
positively for insulin or glucagon. 
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Electronic Supplementary Material 2. Extended image plate Ki67+ Insulin+ cells 
 
ESM 2. Photomicrographs of islets from type 1 diabetes patients stained using the 
combination technique to determine the cell type of the Ki67+ nuclei. (a) An islet showing 
insulin (green), glucagon (red) and Ki67 (dense black nuclei). The white box highlights the 
area focused on in image (b) which demonstrates a Ki67+, insulin+ cell indicative of a 
proliferating beta cell. (c) A brightfield image of the islet demonstrated in (a) in which the 
Ki67+ nucleus is shown in brown and the tissue is counterstained with hematoxylin (purple). 
The black box highlights the area focused on in image (d). 
 
a b 
d c 
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Electronic Supplementary Material 3. Extended image plate Ki67+ glucagon+ cells 
 
 
ESM 3. Photomicrographs of islets from type 1 diabetes patients stained using the 
combination technique to determine the cell type of the Ki67+ nuclei. (a) An islet showing 
insulin (green), glucagon (red) and Ki67 (dense black nuclei). The white box highlights the 
area focused on in image (b) which demonstrates a Ki67+ glucagon+ cell indicative of a 
proliferating alpha cell. (c) A brightfield image of the islet demonstrated in image (a) which 
shows Ki67+ nuclei in brown and counterstaining with hematoxylin (purple). The black box 
highlights the area focused on in image (d). 
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Electronic Supplementary Material 4. Ki67 and Mcm-2 on tonsil epithelium 
 
Mcm-2 is expressed for a longer period of time during the cell cycle than Ki67. Images (a) 
and (b) show Ki67+ and Mcm-2+ cells of the squamous epithelium of the tonsil respectively. 
Scale bar = 30 µm 
 
a b 
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